Creation of a CAR-T cell therapy RNA vaccine that blocks the progression of tumors with strong stromal reactions

Research Project

Project/Area Number	23K19505
Research Category	Grant-in-Aid for Research Activity Start-up
Allocation Type	Multi-year Fund
Review Section	0901:Oncology and related fields
Research Institution	Osaka University
Principal Investigator	孟思昆大阪大学, 大学院医学系研究科, 特任研究員 (50977204)
Project Period (FY)	2023-08-31 – 2025-03-31
Project Status	Granted (Fiscal Year 2023)
Budget Amount *help	¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000) Fiscal Year 2024: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000) Fiscal Year 2023: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Keywords	CAR-T細胞
Outline of Research at the Start	上皮性悪性腫瘍・軟部組織腫瘍に対し、腫瘍微小環境で最も重要である腫瘍随伴線維芽細胞（Cancer associated fibroblast, CAF）を標的にする「FAP-CARを搭載したCD5/LNP」を用いて前臨床薬効薬理試験を行う。さらに安全性試験の実施とProof-of-Concept(POC)の取得を通じ、mRNAワクチンCAR-T細胞療法が固形腫瘍へ応用可能性であるか、明らかにする。